Molecular dynamic simulations reveal suboptimal binding of salbutamol in T164I variant of β2 adrenergic receptor

PLoS One. 2017 Oct 20;12(10):e0186666. doi: 10.1371/journal.pone.0186666. eCollection 2017.


The natural variant C491T (rs1800088) in ADRB2 gene substitutes Threonine to Isoleucine at 164th position in β2AR and results in receptor sequestration and altered binding of agonists. Present investigation pursues to identify the effect of T164I variation on function and structure of β2AR through systematic computational approaches. The study, in addition, addresses altered binding of salbutamol in T164I variant through molecular dynamic simulations. Methods involving changes in free energy, solvent accessibility surface area, root mean square deviations and analysis of binding cavity revealed structural perturbations in receptor to incur upon T164I substitution. For comprehensive understanding of receptor upon substitution, OPLS force field aided molecular dynamic simulations were performed for 10 ns. Simulations revealed massive structural departure for T164I β2AR variant from the native state along with considerably higher root mean square fluctuations of residues near the cavity. Affinity prediction by molecular docking showed two folds reduced affinity of salbutamol in T164I variant. To validate the credibility docking results, simulations for ligand-receptor complex were performed which demonstrated unstable salbutamol-T164I β2AR complex formation. Further, analysis of interactions in course of simulations revealed reduced ligand-receptor interactions of salbutamol in T164I variant. Taken together, studies herein provide structural rationales for suboptimal binding of salbutamol in T164I variant through integrated molecular modeling approaches.

MeSH terms

  • Adrenergic beta-2 Receptor Agonists / pharmacology*
  • Albuterol / metabolism*
  • Molecular Dynamics Simulation
  • Protein Binding
  • Receptors, Adrenergic, beta-2 / metabolism*


  • Adrenergic beta-2 Receptor Agonists
  • Receptors, Adrenergic, beta-2
  • Albuterol

Grant support

The present manuscript is a part of the PhD work of authors Anuraj Nayarisseri and Srinivas Bandaru, which is a purely non-commercial / non-funded work.